Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia

[1]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[2]  Xilin Sun,et al.  Tumor Hypoxia Imaging , 2011, Molecular Imaging and Biology.

[3]  C. Koch,et al.  Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.

[4]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[5]  Valerie A Longo,et al.  Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts , 2010, PloS one.

[6]  C. Ling,et al.  Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. , 2008, Cancer research.

[7]  Johan Bussink,et al.  Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.

[8]  Robert J Gillies,et al.  A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. , 2011, Cancer research.

[9]  Andrea Scozzafava,et al.  Inhibition of carbonic anhydrase IX: a new strategy against cancer. , 2009, Anti-cancer agents in medicinal chemistry.

[10]  J. Kaanders,et al.  Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Andrew K. Dunn,et al.  A Time Domain Fluorescence Tomography System for Small Animal Imaging , 2008, IEEE Transactions on Medical Imaging.

[12]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Pastorek,et al.  Cancer-associated carbonic anhydrases and their inhibition. , 2008, Current pharmaceutical design.

[14]  S. Pastoreková,et al.  Tumor-associated carbonic anhydrases and their clinical significance. , 2006, Advances in clinical chemistry.

[15]  Shingo Matsumoto,et al.  Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302 , 2015, Cancer & metabolism.

[16]  C. Supuran,et al.  Carbonic Anhydrases as Targets for Medicinal Chemistry , 2007 .

[17]  A. Harris,et al.  Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. , 2001, Cancer research.

[18]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[19]  J. Bussink,et al.  Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters. , 2004, International journal of radiation oncology, biology, physics.

[20]  S M Evans,et al.  Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. , 2000, International journal of radiation oncology, biology, physics.

[21]  C. Koch,et al.  Prognostic significance of tumor oxygenation in humans. , 2003, Cancer letters.

[22]  J. Pouysségur,et al.  Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. , 2009, Cancer research.

[23]  P. Lambin,et al.  Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  Jongphil Kim,et al.  The computation of bivariate normal and t probabilities, with application to comparisons of three normal means , 2013, Comput. Stat. Data Anal..

[25]  P H Watson,et al.  Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma , 2003, British Journal of Cancer.

[26]  W. Oyen,et al.  Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  A S Kennedy,et al.  Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. , 1998, Gynecologic oncology.

[28]  R. Gillies,et al.  Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. , 2005, Analytical biochemistry.

[29]  J. Vermorken,et al.  Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. , 2007, The oncologist.

[30]  M. Lerman,et al.  Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. , 2001, Cancer research.

[31]  C. Supuran,et al.  Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype , 2007, British Journal of Cancer.

[32]  S M Evans,et al.  Interlaboratory variation in oxygen tension measurement by Eppendorf “Histograph” and comparison with hypoxic marker , 1997, Journal of surgical oncology.

[33]  K. Chayama,et al.  Expression of VEGF‐C and VEGF‐D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma , 2004, Cancer science.

[34]  Robert J Gillies,et al.  Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes , 2011, Clinical Cancer Research.

[35]  J. Humm,et al.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.

[36]  Johan Bussink,et al.  Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  P. Sutphin,et al.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.

[38]  J. Pastorek,et al.  Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. , 2010, Current pharmaceutical design.

[39]  R. Gatenby,et al.  Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. , 1988, International journal of radiation oncology, biology, physics.

[40]  Christophe Van de Wiele,et al.  Molecular imaging of hypoxia with radiolabelled agents , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  Damien J. Ferraro,et al.  Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer , 2011, Clinical Cancer Research.

[42]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[43]  W. Sly,et al.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.

[44]  C. Supuran,et al.  Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH , 2004, FEBS letters.

[45]  G. Cook,et al.  Oncological molecular imaging: nuclear medicine techniques. , 2003, The British journal of radiology.

[46]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[47]  M. Knopp,et al.  PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody , 2009, Therapeutic advances in urology.

[48]  M C Weissler,et al.  Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. , 1998, Cancer research.